Table 1.

Concepts and progress of irRC

Concepts of irRC
  • Confirmation of progression via a subsequent scan to detect delayed responses

  • Measuring new lesions to include them into the total tumor volume

  • Accounting for durable stable disease as benefit

  • Treating beyond conventional progression if the clinical situation allows

Advances of irRC utility between 2009 and 2015
  • Transferability of irRC concepts between WHO (bidimensional) and RECIST (unidimensional)

  • Application of irRC to diseases beyond melanoma

  • Inclusion of irRC concepts into regulatory guidance documents of the FDA and EMA

  • Expansion of irRC concepts beyond the initial implementation

  • Demonstration of an irRC-detected class effect across several immunotherapies